We work to improve the success of embryo transfers
We detect endometrial receptivity non-invasively and immediately
Infertility, a highly prevalent condition affecting
Couples
1 in every 6
People
190 Million
Young Adults
The most frequent health problem in adults in reproductive age
In Vitro Fertilisation success is still low, making the treatment
Long
3 cycles > 2 years
Expensive
From 8000 to 10,000 €/cycle
Emotionally draining
Stress is the leading cause of the treatment abandonment
Unmet Clinical Need: Detecting uterine readiness for Embryo Transfer
One of the leading causes of IVF failure is embryo transfer, with a live birth rate below 30%. It is generally accepted that in the presence of high-quality embryos, the uterus determines the success of embryo implantation. Nowadays, the selection of high-quality embryos is solved; but assessing the uterine readiness is done by counting days. Therefore an urgent unmet clinical need is to provide accuracy in detecting uterine receptivity and embryo-uterine synchrony to improve embryo implantation rates and IVF success.
We are aiming to boost Embryo Transfer success rates making IVF treatments faster, healthier, and more affordable.
A first-in-class medical device developed to detect uterine readiness for embryo transfer in situ, non-invasively, and immediately.
ProblemS TO SOLVE
- Live birth rates per embryo transfer below 30% make IVF a long and frustrating process.
- Repeated trial and error IVF cycles representing a high economic and psychological burden for patients, causing treatment abandonment.
- Differential access to fertility treatments contributes to health inequity and gender imbalance.
Our approach
- Breakthrough technology to assess uterine readiness for embryo transfer non-invasively without interfering with the patient’s journey.
- Embryo transfer effectiveness to achieve optimal IVF results.
- Support natural cycles and single embryo transfer for healthier pregnancy and neonatal outcomes.
Monica de la Vega
Co-founder
Ph.D in Biochemistry
Innovation in health Entrepreneur
Luis Manuel Artiles
Co-founder
Ph.D. en Mathematics
IA/ML Expert Entrepreneur
Dr. Julio Herrero
Head of the Assisted Reproduction Section
Vall d’Hebron Hospital
CEO CRA Barcelona
Dr. Melchor Carbonell
Principal Investigator Expert in IVF and implantation failures
Vall d’Hebron Hospital
Dra. Anna Teixidó
Clinical researcher
IVF Specialist Gynecologist
Vall d’Hebron Hospital
Gina Abelló
PhD in Biology
Clinical Studies Manager
Expert in developmental biology
Sussette Padilla
PhD in Chemistry
Regulatory and Quality Manager
Medical product expert
Adriano Feliu
Marketing Specialist Branding and Product Design Graduate on film Direction
Partners, Sponsors and Supporters
News & Recommended Articles
Manina Medtech, engendrada per fer néixer més nadons
Amb la ronda de finançament estan fent proves clíniques de dispositiu mèdic ANNA PINTER - BARCELONA Manina Medtech és una empresa derivada (spin off) de la Vall d’Hebron que ha emparellat la intel·ligència artificial (IA) i la investigació en reproducció assistida. De...
Manina Medtech, spin-off de Vall d’Hebron, cierra una ronda de inversión para desarrollar un dispositivo médico para aumentar el éxito de la Fecundación in Vitro
Manina Medtech, spin-off de Vall d’Hebron, acaba de cerrar su primera ronda de financiación pre-semilla (pre-seed) de la mano de Medex Partner como inversor principal (lead Investor), para el desarrollo de un dispositivo médico de tipo para uso en la consulta...
Top 18 InnoStars Awards start-ups in 2023
Manina Medtech advance to the semifinals of the EIT Health InnoStars awards.
Tech4Eva: Announcing 2023 cohort
Manina Medtech has been selected to participate in the global Femtech accelerator Tech4eva!
Manina Medtech participará en la 5a edición de CRAASH Barcelona
CRAASH Barcelona, el programa de aceleración impulsado por Biocat en colaboración con el CIMIT (Boston), ha iniciado su 5ª edición con un encuentro celebrado del 12 al 14 de septiembre en el Pier 01 y Pier 03 de Tech Barcelona, donde han asistido participantes y mentores.
La startup catalana Manina Medtech crea una tecnologia per augmentar la ràtio d’embarassos en la reproducció ‘in vitro’
La companyia ha desenvolupat un test instantani no invasiu que, juntament amb un algoritme que utilitza intel·ligència artificial, és capaç de determinar el moment on l’úter de la dona és més probable que accepti la implantació de l’embrió i fer-ne la transferència
La catalana Manina Medtech idea tecnología que facilita reproducción in vitro
La empresa emergente catalana Manina Medtech ha ideado una tecnología que, mediante el uso de inteligencia artificial, facilita la reproducción ‘in vitro’ al aumentar el porcentaje de éxito de estos procesos.
Making IVF faster and more affordable
Embryo transfer effectiveness to achieve optimal IVF results.